LivingGLP1
Study S002296

Evaluation of the Glucoregulatory Effects of GLP-1 Receptor Activation in Patients With Type 2 Diabetes Mellitus

ClinicalTrials.gov record

Registration

Registration
NCT01373450
Study type
INTERVENTIONAL
Allocation
RANDOMIZED
Phase
PHASE1
Masking
TRIPLE
Status
COMPLETED
Enrollment
12
Start
2011-06
Primary completion
2011-07
Lead sponsor
Merck Sharp & Dohme LLC
Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG:Oxyntomodulin; DRUG:Liraglutide 0.6 mg; DRUG:Liraglutide 1.2 mg; DRUG:Placebo for Oxyntomodulin; DRUG:Placebo for Liraglutide
Results posted
TRUE

Registered primary outcomes

  • Change From Baseline in Time-weighted Average of Glucose Measured by Area Under the Curve (AUC) After a Single Dose of Oxyntomodulin (OXM) [Baseline and during GGI at time points 0, 20, 40, 60, 80, 100, 120, 140, 160 and 165 minutes]
  • Change From Baseline in Maximum Ambient Glucose Concentration (Gmax) After a Single Dose of OXM [Baseline and up to 160 minutes after start of GGI]
  • Change From Baseline in Beta Cell Sensitivity to Glucose (Φ) After a Single Dose of OXM [Baseline and up to160 minutes after start of GGI]

Linked records (2)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.
RecordTitleYearDesignIdentifiersLink basis
R0023885Native Oxyntomodulin Has Significant Glucoregulatory Effects Independent of Weight Loss in Obese Humans With and Without Type 2 Diabetes.
Shankar SS, Diabetes
2018Randomized trialPMID 29545266DOIcites ClinicalTrials.gov:NCT01373450; registry reference DERIVED:29545266
R0028793Linearity of β-cell response across the metabolic spectrum and to pharmacology: insights from a graded glucose infusion-based investigation series.
Shankar SS, American journal of physiology. Endocrinology and metabolism
2016Other trialPMID 27072496DOIcites ClinicalTrials.gov:NCT01373450; registry reference DERIVED:27072496